|18.70||-0.0900||-0.48%||Vol 118.63K||1Y Perf 345.95%|
|Apr 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||28.63||Analyst Rating||Strong Buy 1.29|
|Potential %||53.10||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 54.68|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||603.26M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||69.91||Earnings Date||11th May 2021|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th May 2021|
|Estimated EPS Next Report||-0.24|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||164.37K|
|Avg. Monthly Volume||218.09K|
|Avg. Quarterly Volume||177.90K|
IDEAYA Biosciences Inc. (NASDAQ: IDYA) stock closed at 18.7 per share at the end of the most recent trading day (a -0.48% change compared to the prior day closing price) with a volume of 137.66K shares and market capitalization of 603.26M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 58 people. IDEAYA Biosciences Inc. CEO is Yujiro S. Hata.
The one-year performance of IDEAYA Biosciences Inc. stock is 345.95%, while year-to-date (YTD) performance is 33.57%. IDYA stock has a five-year performance of %. Its 52-week range is between 4.25 and 24.92, which gives IDYA stock a 52-week price range ratio of 69.91%
IDEAYA Biosciences Inc. currently has a PE ratio of -14.60, a price-to-book (PB) ratio of 3.54, a price-to-sale (PS) ratio of 29.32, a price to cashflow ratio of 9.70, a PEG ratio of 2.32, a ROA of -16.38%, a ROC of -25.95% and a ROE of -22.43%. The company’s profit margin is -%, its EBITDA margin is -446.40%, and its revenue ttm is $19.54 Million , which makes it $0.61 revenue per share.
Of the last four earnings reports from IDEAYA Biosciences Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. IDEAYA Biosciences Inc.’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for IDEAYA Biosciences Inc. is Strong Buy (1.29), with a target price of $28.63, which is +53.10% compared to the current price. The earnings rating for IDEAYA Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IDEAYA Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IDEAYA Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.27, ATR14 : 1.59, CCI20 : -129.72, Chaikin Money Flow : 0.05, MACD : 0.28, Money Flow Index : 40.82, ROC : -17.44, RSI : 59.04, STOCH (14,3) : 17.62, STOCH RSI : 0.29, UO : 34.10, Williams %R : -82.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IDEAYA Biosciences Inc. in the last 12-months were: Jason Throne (Sold 8 368 shares of value $98 994 ), Mark Lackner (Option Excercise at a value of $63 205), Mark Lackner (Sold 12 469 shares of value $204 178 ), Michael Dillon (Option Excercise at a value of $68 003), Michael Dillon (Sold 5 000 shares of value $103 697 ), Paul Stone (Option Excercise at a value of $42 966), Paul Stone (Sold 9 300 shares of value $167 150 ), Yujiro S. Hata (Option Excercise at a value of $34 480)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.